- Company
-
- Aifinyo AG
- Aixtron SE
- Berentzen Gruppe AG
- Amadeus Fire AG
- Brain Biotech AG
- Carl Zeiss Meditec AG
- Cherry SE
- Deutz AG
- Edag Engineering Group AG
- ElringKlinger AG
- Encavis AG
- Energiekontor AG
- Gerresheimer AG
- Hypoport SE
- Jost Werke SE
- Knaus Tabbert AG
- LEG Immobilien SE
- Mister Spex SE
- Mountain Alliance AG
- Mutares SE
- Nemetschek SE
- PSI Software SE
- Rational AG
- RENK Group AG
- Schaltbau Holding AG
- SFC Energy AG
- Sixt SE
- Talanx AG
- USU Software AG
- Varta AG
- voxeljet AG
- Verve Group SE
- Wacker Chemie AG
- Zeal Network SE
- Presentations
- Index
- Blog
- About
May 28, 2026
11:25 
BRAIN Biotech AG 6M FY 2025/26: Key Takeaways
Presented by Michael Schneiders, CFO
In this latest financial results presentation on seat11a, Michael Schneiders of BRAIN Biotech AG presents the company’s 6M FY 2025/26 financial results and provides an update on operational developments across its enzyme business and BioIncubator activities.
Industrial Biotechnology Platform with Two-Pillar Structure
BRAIN Biotech continues to position itself as a provider of industrial biotechnology solutions, combining enzyme technologies, microbial systems, and biotechnology-driven industrial applications across food, life sciences, chemicals, health, and sustainability-related markets.
The company operates through its two-pillar structure consisting of the operational enzyme business BRAINBiocatalysts and the innovation-focused BRAINBioIncubator platform.
Sequential Growth in the Enzyme Business
During the first six months of FY 2025/26, the company reported sequential growth in the enzyme business during Q2 compared with Q1, while the enzyme-related CRO business remained solid.
BRAIN Biotech also successfully commissioned its new Netherlands production facility on time and within budget, with management expecting operational synergies and efficiency improvements from the site going forward.
The continued development of the enzyme business remains strategically important for the company as it seeks to expand its position in industrial biotechnology and higher-value biocatalyst applications.
BioIncubator Advances Scientific and Strategic Initiatives
Within the BioIncubator segment, the company continued to advance several strategic and scientific initiatives.
BRAIN Biotech received a European patent for its genome editing nuclease BMC®, which management highlighted as opening additional licensing opportunities for the CRO business and biotechnology applications.
In addition, portfolio company Akribion Therapeutics published research in Nature magazine related to RNA-triggered cell killing using CRISPR-Cas12a2 technology, underlining ongoing scientific progress within the BioIncubator ecosystem.
Improved EBITDA and Ongoing Cost Discipline
Financially, revenues reached €23.4 million during the first six months, while adjusted EBITDA improved significantly to approximately break-even.
Management highlighted milestone income, operational integration measures, and ongoing cost control as important factors during the reporting period.
The company continues to emphasize operational discipline, efficiency improvements, and careful capital allocation as part of its broader strategy to strengthen financial resilience while advancing biotechnology innovation.
Guidance and Mid-Term Targets Confirmed
BRAIN Biotech also confirmed its FY 2025/26 guidance and maintained its broader mid-term targets presented during the Capital Markets Day in December 2024.
These targets include long-term growth ambitions for the enzyme business and continued expansion across biotechnology and bioeconomy applications.
Investor Perspective
For investors, BRAIN Biotech remains positioned around several structural growth themes, including industrial biotechnology, sustainable production processes, enzyme innovation, genome editing technologies, and bioeconomy applications.
The combination of a growing operational enzyme business and a scientifically driven BioIncubator platform continues to define the broader investment case, while management remains focused on balancing innovation with improving financial discipline and operational execution.
Conclusion
BRAIN Biotech AG’s 6M FY 2025/26 financial results presentation highlights continued progress across both operational and scientific activities.
Sequential growth in the enzyme business, commissioning of the new production facility, advances within the BioIncubator portfolio, and improved EBITDA performance underline the company’s ongoing development as an industrial biotechnology platform focused on scalable growth, operational efficiency, and innovation-driven value creation.
Chapters
- Successful niche-player in research, development and production of enzyme
- Key Messages 6M FY 2025/26
- NL Production Plant Commissioned On-Time and In-Budget
- European Patent Granted for Editing Nuclease BMC
- Akribion Therapeutics Publishes in Nature Magazine
- Financial Highlights 6M FY 2025/26 at a Glance
- Our Targets – Unchanged Guidance
- Why you should think about investing into BRAIN Biotech
- Financial Calendar – Next Investor Events
Resources
Host
Share
T&C:
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
Reviews for BRAIN Biotech AG Financial Results H1 2025 / 26 | Enzymes, CRISPR, BioIncubator projects, and bioeconomy innovation.
There are currently no reviews for BRAIN Biotech AG Financial Results H1 2025 / 26 | Enzymes, CRISPR, BioIncubator projects, and bioeconomy innovation.
(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Unlock the insights of top publicly listed companies with seat11a.com